adx her2 mutation detection kit (amoy diagnostics, xiamen, china)  (Amoy Diagnostics)

Journal: Cancer Medicine

Article Title: A retrospective study of first‐line therapy and subsequent pyrotinib treatment in advanced lung adenocarcinoma with HER2 mutations

doi: 10.1002/cam4.7335

Figure Lengend Snippet: Baseline Characteristics of HER2‐Mutant patients in first‐line treatment.

Article Snippet: The ADx HER2 Mutation Detection Kit (Amoy Diagnostics, Xiamen, China) can detect various HER2 mutation types, including 12‐bp exon 20 insertion, G776 mutations, 9‐bp exon 20 insertion, V777L mutation, and L755p mutation.

Techniques:

Journal: Cancer Medicine

Article Title: A retrospective study of first‐line therapy and subsequent pyrotinib treatment in advanced lung adenocarcinoma with HER2 mutations

doi: 10.1002/cam4.7335

Figure Lengend Snippet: Kaplan–Meier survival curves of PFS in HER2 mutation. (A) Chemotherapy + ICIs versus chemotherapy; (B) PD‐L1 Negative versus PD‐L1 Positive; (C) chemotherapy + bevacizumab versus chemotherapy; (D) chemotherapy + bevacizumab versus chemotherapy + ICIs; (E) pyrotinib versus chemotherapy; (F) pyrotinib versus chemotherapy + ICIs.

Article Snippet: The ADx HER2 Mutation Detection Kit (Amoy Diagnostics, Xiamen, China) can detect various HER2 mutation types, including 12‐bp exon 20 insertion, G776 mutations, 9‐bp exon 20 insertion, V777L mutation, and L755p mutation.

Techniques: Mutagenesis

Journal: Cancer Medicine

Article Title: A retrospective study of first‐line therapy and subsequent pyrotinib treatment in advanced lung adenocarcinoma with HER2 mutations

doi: 10.1002/cam4.7335

Figure Lengend Snippet: Clinical and pathological characteristics of HER2‐mutant patients treated with pyrotinib after first‐line treatment progression in this study.

Article Snippet: The ADx HER2 Mutation Detection Kit (Amoy Diagnostics, Xiamen, China) can detect various HER2 mutation types, including 12‐bp exon 20 insertion, G776 mutations, 9‐bp exon 20 insertion, V777L mutation, and L755p mutation.

Techniques:

Journal: Cancer Medicine

Article Title: A retrospective study of first‐line therapy and subsequent pyrotinib treatment in advanced lung adenocarcinoma with HER2 mutations

doi: 10.1002/cam4.7335

Figure Lengend Snippet: HER2‐mutant patients treated with pyrotinib after first‐line treatment progression. (A) Survival benefits of Pyrotinib based on treatment data and line of treatment. (B) Kaplan–Meier survival curves of PFS based on first‐line treatment PFS; (C) univariate analysis; (D) multivariate analysis.

Article Snippet: The ADx HER2 Mutation Detection Kit (Amoy Diagnostics, Xiamen, China) can detect various HER2 mutation types, including 12‐bp exon 20 insertion, G776 mutations, 9‐bp exon 20 insertion, V777L mutation, and L755p mutation.

Techniques: Mutagenesis

Journal: Cancer Medicine

Article Title: A retrospective study of first‐line therapy and subsequent pyrotinib treatment in advanced lung adenocarcinoma with HER2 mutations

doi: 10.1002/cam4.7335

Figure Lengend Snippet: Summary of genomic landscape and clinical features in HER2‐Mutant NSCLC with immunotherapy. (A) Mutation frequency; (B) Kaplan–Meier survival curves of OS; (C) OncoPrint that top 20 gene alterations.

Article Snippet: The ADx HER2 Mutation Detection Kit (Amoy Diagnostics, Xiamen, China) can detect various HER2 mutation types, including 12‐bp exon 20 insertion, G776 mutations, 9‐bp exon 20 insertion, V777L mutation, and L755p mutation.

Techniques: Mutagenesis

Journal: Cancer Medicine

Article Title: A retrospective study of first‐line therapy and subsequent pyrotinib treatment in advanced lung adenocarcinoma with HER2 mutations

doi: 10.1002/cam4.7335

Figure Lengend Snippet: Reported retrospective studies on the efficacy of first‐line treatment for advanced NSCLC with HER2‐Mutant.

Article Snippet: The ADx HER2 Mutation Detection Kit (Amoy Diagnostics, Xiamen, China) can detect various HER2 mutation types, including 12‐bp exon 20 insertion, G776 mutations, 9‐bp exon 20 insertion, V777L mutation, and L755p mutation.

Techniques: Control

Journal: Cancer Medicine

Article Title: A retrospective study of first‐line therapy and subsequent pyrotinib treatment in advanced lung adenocarcinoma with HER2 mutations

doi: 10.1002/cam4.7335

Figure Lengend Snippet: Baseline Characteristics of HER2‐Mutant patients in first‐line treatment.

Article Snippet: In the first‐line treatment cohort, the inclusion criteria were as follows: (1) age ≥ 18 years, (2) HER2 mutations detected at the time of initial diagnosis through next‐generation sequencing (NGS) or ADx HER2 Mutation Detection Kit (Amoy Diagnostics, Xiamen, China) in tumor tissue or liquid biopsy samples, (3) without EGFR sensitizing mutations and ALK rearrangements, and (4) receipt of first‐line treatment.

Techniques:

Journal: Cancer Medicine

Article Title: A retrospective study of first‐line therapy and subsequent pyrotinib treatment in advanced lung adenocarcinoma with HER2 mutations

doi: 10.1002/cam4.7335

Figure Lengend Snippet: Kaplan–Meier survival curves of PFS in HER2 mutation. (A) Chemotherapy + ICIs versus chemotherapy; (B) PD‐L1 Negative versus PD‐L1 Positive; (C) chemotherapy + bevacizumab versus chemotherapy; (D) chemotherapy + bevacizumab versus chemotherapy + ICIs; (E) pyrotinib versus chemotherapy; (F) pyrotinib versus chemotherapy + ICIs.

Article Snippet: In the first‐line treatment cohort, the inclusion criteria were as follows: (1) age ≥ 18 years, (2) HER2 mutations detected at the time of initial diagnosis through next‐generation sequencing (NGS) or ADx HER2 Mutation Detection Kit (Amoy Diagnostics, Xiamen, China) in tumor tissue or liquid biopsy samples, (3) without EGFR sensitizing mutations and ALK rearrangements, and (4) receipt of first‐line treatment.

Techniques: Mutagenesis

Journal: Cancer Medicine

Article Title: A retrospective study of first‐line therapy and subsequent pyrotinib treatment in advanced lung adenocarcinoma with HER2 mutations

doi: 10.1002/cam4.7335

Figure Lengend Snippet: Clinical and pathological characteristics of HER2‐mutant patients treated with pyrotinib after first‐line treatment progression in this study.

Article Snippet: In the first‐line treatment cohort, the inclusion criteria were as follows: (1) age ≥ 18 years, (2) HER2 mutations detected at the time of initial diagnosis through next‐generation sequencing (NGS) or ADx HER2 Mutation Detection Kit (Amoy Diagnostics, Xiamen, China) in tumor tissue or liquid biopsy samples, (3) without EGFR sensitizing mutations and ALK rearrangements, and (4) receipt of first‐line treatment.

Techniques:

Journal: Cancer Medicine

Article Title: A retrospective study of first‐line therapy and subsequent pyrotinib treatment in advanced lung adenocarcinoma with HER2 mutations

doi: 10.1002/cam4.7335

Figure Lengend Snippet: HER2‐mutant patients treated with pyrotinib after first‐line treatment progression. (A) Survival benefits of Pyrotinib based on treatment data and line of treatment. (B) Kaplan–Meier survival curves of PFS based on first‐line treatment PFS; (C) univariate analysis; (D) multivariate analysis.

Article Snippet: In the first‐line treatment cohort, the inclusion criteria were as follows: (1) age ≥ 18 years, (2) HER2 mutations detected at the time of initial diagnosis through next‐generation sequencing (NGS) or ADx HER2 Mutation Detection Kit (Amoy Diagnostics, Xiamen, China) in tumor tissue or liquid biopsy samples, (3) without EGFR sensitizing mutations and ALK rearrangements, and (4) receipt of first‐line treatment.

Techniques: Mutagenesis

Journal: Cancer Medicine

Article Title: A retrospective study of first‐line therapy and subsequent pyrotinib treatment in advanced lung adenocarcinoma with HER2 mutations

doi: 10.1002/cam4.7335

Figure Lengend Snippet: Summary of genomic landscape and clinical features in HER2‐Mutant NSCLC with immunotherapy. (A) Mutation frequency; (B) Kaplan–Meier survival curves of OS; (C) OncoPrint that top 20 gene alterations.

Article Snippet: In the first‐line treatment cohort, the inclusion criteria were as follows: (1) age ≥ 18 years, (2) HER2 mutations detected at the time of initial diagnosis through next‐generation sequencing (NGS) or ADx HER2 Mutation Detection Kit (Amoy Diagnostics, Xiamen, China) in tumor tissue or liquid biopsy samples, (3) without EGFR sensitizing mutations and ALK rearrangements, and (4) receipt of first‐line treatment.

Techniques: Mutagenesis

Journal: Cancer Medicine

Article Title: A retrospective study of first‐line therapy and subsequent pyrotinib treatment in advanced lung adenocarcinoma with HER2 mutations

doi: 10.1002/cam4.7335

Figure Lengend Snippet: Reported retrospective studies on the efficacy of first‐line treatment for advanced NSCLC with HER2‐Mutant.

Article Snippet: In the first‐line treatment cohort, the inclusion criteria were as follows: (1) age ≥ 18 years, (2) HER2 mutations detected at the time of initial diagnosis through next‐generation sequencing (NGS) or ADx HER2 Mutation Detection Kit (Amoy Diagnostics, Xiamen, China) in tumor tissue or liquid biopsy samples, (3) without EGFR sensitizing mutations and ALK rearrangements, and (4) receipt of first‐line treatment.

Techniques: Control